



**Erratum. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care 2021;44:1334–1343**

<https://doi.org/10.2337/dc22-er05a>

*Yvo J.M. Op den Kamp, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Russell Esterline, Matthijs K.C. Hesselink, Joris Hoeks, Vera B. Schrauwen-Hinderling, Bas Havekes, Jan Oscarsson, Esther Phielix, and Patrick Schrauwen*

In the article cited above, a composition error resulted in the omission of references 30–35, and the reference Cusi et al. was listed as reference 30. The reference number for Cusi et al. is 36, and the correct references 30–35 are as follows:

30. Scholtes RA, Muskiet MHA, van Baar MJB, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. *Diabetes Care* 2021;44:440–447
31. Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. *Nat Rev Endocrinol* 2017;13:572–587
32. Wefers J, Connell NJ, Fealy CE, et al. Daynight rhythm of skeletal muscle metabolism is disturbed in older, metabolically compromised individuals. *Mol Metab* 2020;41:101050
33. Lin X, Zhang X, Guo J, et al. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc* 2015;4:e002014
34. Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. *Diabetes Technol Ther* 2014;16:137–144
35. Tuominen JA, Ebeling P, Bourey R, et al. Postmarathon paradox: insulin resistance in the face of glycogen depletion. *Am J Physiol* 1996;270:E336–E343

The online version of the article (<https://doi.org/10.2337/dc20-2887>) has been updated with the correct references.